Petros WP - Search Results

1

Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.

Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM, et al. Furman WL, et al. Among authors: petros wp. J Clin Oncol. 1991 Jun;9(6):1022-8. doi: 10.1200/JCO.1991.9.6.1022. J Clin Oncol. 1991. PMID: 2033415

2

Pharmacokinetics and pharmacodynamics of anticancer agents: contributions to the therapy of childhood cancer.

Petros WP, Evans WE. Petros WP, et al. Pharmacotherapy. 1990;10(5):313-25. Pharmacotherapy. 1990. PMID: 2235668 Review.

3

Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.

Petros WP, Rodman JH, Mirro J Jr, Evans WE. Petros WP, et al. Cancer Chemother Pharmacol. 1991;27(5):397-400. doi: 10.1007/BF00688865. Cancer Chemother Pharmacol. 1991. PMID: 1999001

4

Clinical pharmacology of cancer chemotherapy in children.

Evans WE, Petros WP, Relling MV, Crom WR, Madden T, Rodman JH, Sunderland M. Evans WE, et al. Among authors: petros wp. Pediatr Clin North Am. 1989 Oct;36(5):1199-230. doi: 10.1016/s0031-3955(16)36765-7. Pediatr Clin North Am. 1989. PMID: 2677939 Review.

5

Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.

Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE. Petros WP, et al. Pharmacotherapy. 1992;12(4):273-7. Pharmacotherapy. 1992. PMID: 1518726

6

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.

Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Relling MV, et al. Among authors: petros wp. Clin Pharmacol Ther. 1991 Sep;50(3):308-13. doi: 10.1038/clpt.1991.141. Clin Pharmacol Ther. 1991. PMID: 1680593

7

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.

Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK. Evans WE, et al. Among authors: petros wp. J Pharmacol Exp Ther. 1992 Jan;260(1):71-7. J Pharmacol Exp Ther. 1992. PMID: 1731053

8

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.

Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Evans WE, et al. Among authors: petros wp. Clin Pharmacol Ther. 1989 May;45(5):568-73. doi: 10.1038/clpt.1989.74. Clin Pharmacol Ther. 1989. PMID: 2721111

9

Pharmacogenomics in cancer therapy: is host genome variability important?

Petros WP, Evans WE. Petros WP, et al. Trends Pharmacol Sci. 2004 Sep;25(9):457-64. doi: 10.1016/j.tips.2004.07.007. Trends Pharmacol Sci. 2004. PMID: 15559247 Review.

10

Carboplatin pharmacokinetics in young children with brain tumors.

Tonda ME, Heideman RL, Petros WP, Friedman HS, Murry DJ, Rodman JH. Tonda ME, et al. Among authors: petros wp. Cancer Chemother Pharmacol. 1996;38(5):395-400. doi: 10.1007/s002800050502. Cancer Chemother Pharmacol. 1996. PMID: 8765431 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters